CAPRA
Research type
Research Study
Full title
Measurement of RNA signature for DNA repair damage from circulating tumour cells (CTCs) in castrate-resistant prostate cancer treated with Ra-223.
IRAS ID
213768
Contact name
Ananya Choudhury
Contact email
Sponsor organisation
University of Manchester
Duration of Study in the UK
3 years, 5 months, 31 days
Research summary
We will develop a way of predicting patient responses to Ra223 in a small blood sample using a molecular (RNA) signature measured in circulating prostate cancer cells (CTCs). This approach, called a ‘liquid biopsy’, can be used before, during and after treatment as it is easily repeated and is less invasive than taking a tumour sample. The main study aim is to make a simple blood test using the CTC RNA signature allowing doctors to know which prostate cancer patients are most likely to respond to Ra223 and spare patients’ toxicity if unlikely to respond. We will examine other molecules in the blood. These molecules, alongside CTCs, will be used to monitor patients during treatment. We think that during treatment, these molecules will decrease in responding patients and increase in resistant patients. We hope that molecule measurements may reveal which type of prostate cancer cells are sensitive and which are resistant to Ra223. We aim to develop a panel of blood tests to help doctors make better treatment decisions for their patients. We will also use patient CTCs to develop mouse prostate cancer models that can be used to understand treatment resistance and test new treatments.
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
17/EM/0039
Date of REC Opinion
23 Jan 2017
REC opinion
Favourable Opinion